as 11-05-2025 11:16am EST
MapLight Therapeutics Inc is a biopharmaceutical company. The company is focused on improving the lives of patients suffering from debilitating central nervous system, or CNS, disorders. The company is engaged in psychiatry and neuroscience research to address the lack of circuit-specific pharmacotherapies available for patients. The product candidates of the company include ML-007C-MA, ML-004, ML-021, ML-009, and other pipeline products.
| Founded: | 2018 | Country: | United States |
| Employees: | N/A | City: | N/A |
| Market Cap: | 700.6M | IPO Year: | 2025 |
| Target Price: | N/A | AVG Volume (30 days): | 780.2K |
| Analyst Decision: | N/A | Number of Analysts: | N/A |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | -121.50 | EPS Growth: | N/A |
| 52 Week Low/High: | $15.00 - $20.86 | Next Earning Date: | 11-28-2025 |
| Revenue: | N/A | Revenue Growth: | N/A |
| Revenue Growth (this year): | N/A | Revenue Growth (next year): | N/A |
The information presented on this page, "MPLT MapLight Therapeutics Inc. Common Stock - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.